Cognition
Community
The regulatory proposal describes cognitive-enhancement marketing; it does not establish clinical benefit.1
Mind & sleep
Adamax
Semax-related experimental analogue
No FDA-approved product identified for this exact research entry in the targeted review.
What does it do?
Amino-acid sequence
An exact sequence has not been verified for this formulation.
Reference identity · not independently confirmed14
Length9 amino acids (with modifications)
Molecular weight · Da1,032.24 Da
Pharmacokinetics
Reported half-lifeHuman half-life not verified2
No numerical human elimination estimate was verified for the exact material in this review.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
Regulatory mention is not clinical validation
A New Zealand classification proposal identifies Adamax among marketed ACTH analogues. No exact-compound controlled human study was verified in this targeted search.1
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | 200-300 mcg | 1x daily | Cognitive enhancementReference report | 2-4 weeks | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 300 mcg | 1-2x daily | NeuroprotectionReference report | 2-4 weeks | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 200 mcg | 1x daily (morning) | Mood supportReference report | 2-4 weeks | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| SubQ | 100-200 mcg | 1x daily | Initial trial/assessmentReference report | 2-4 weeks | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| OralOral or Sublingual | 100-200 mg | 1x daily (morning) | Cognitive enhancementReference report | 2-4 weeks | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral or Sublingual | 100-200 mg | 2x daily (morning, early afternoon) | Sustained focusReference report | 2-4 weeks | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral or Sublingual | 100 mg | 1x daily (morning) | Mood supportReference report | 2-4 weeks | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| OralOral or Sublingual | 100 mg | 1x daily | Initial assessmentReference report | 2-4 weeks | 14 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 2-4 weeks
- Break
- 2-4 weeks to prevent tolerance
Reported timing
Morning preferred for cognitive benefits
Oral
- Use period
- 2-4 weeks
- Break
- 2-4 weeks to prevent tolerance
Reported timing
Morning preferred, avoid evening if stimulatory
Side effects & safety
Evidence limitation
The classification proposal does not establish a safe human dose.
1Evidence limitation
Long-term neurologic effects and interactions of the exact modified compound remain unverified.
1Evidence
Parent-compound findings do not prove Adamax effects or oral absorption.
Symptoms
Headache, insomnia, anxiety, mood/mental-status changes, nausea, vomiting, diarrhea, palpitations, hypertension, chest pain or injection infection need assessment.
Pregnancy
Pregnancy/lactation safety unstudied.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
5 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Noopept
Caution reportedOverlapping BDNF-related claims; overstimulation concern.14
Reference report · Pep-Pedia label: Monitor CombinationSemax
Related compoundNot equivalent evidence.14
Reference report · Pep-Pedia label: SimilarP21
Unverified pairingAdamantane-related rationale.14
Reference report · Pep-Pedia label: SynergisticBPC-157
Unverified pairingDifferent targets do not establish safety.14
Reference report · Pep-Pedia label: CompatibleOther medicines or peptides
Not establishedNo exact-product human interaction study was verified; lack of evidence is not evidence of safety.2
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Source temperature: 2-8°C. · Reported post-preparation interval: 14-30 days.
The source describes gentle mixing and avoiding vigorous shaking.
Oral
The source describes oral capsules and sublingual powder or spray.
- Form
- Source describes a prepared product
- Reported parameters
- Reported sublingual contact time: 60–90 seconds. · Capsules or powder: cool, dry room-temperature storage.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite, Fluffy PowderReported appearanceClear Solution After ReconstitutionReported appearanceProper LabelingReported variationSlight CompactionReported concernDiscoloration or YellowingReported concernCloudy After Reconstitution
14Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →Parent Semax findings do not establish Adamax efficacy, brain exposure or safety.1
1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
No human data verifiedCompound identity & other names
Adamax is marketed as a modified Semax-related nootropic. A regulator describes it among ACTH-analogue products, but an Adamax-specific clinical evidence base was not established in this check.
No FDA-approved product identified for this exact research entry in the targeted review.
Semax-related experimental analogue214
Pep-Pedia identity record
9 amino acids (with modifications) · 1,032.24 Da
Ac-Met-Glu-His-Phe-Pro-Gly-Pro-AGly-NH2Reference description; checked chemical identity takes precedence when available.14
How it may work
BDNF/TrkB, neurotransmitter, antioxidant and microtubule mechanisms are proposed, not demonstrated clinical benefits.14
Regulatory mention is not clinical validation
A New Zealand classification proposal identifies Adamax among marketed ACTH analogues. No exact-compound controlled human study was verified in this targeted search.
1Research areas and evidence gaps
- Parent Semax findings do not establish Adamax efficacy, brain exposure or safety.
- A product-specific research-vial quantity was not independently verified in this review.
Additional uses listed by Pep-Pedia
Cognition. Focus, clarity, learning, memory, attention and mental endurance claims.14
Neuroprotection. Synaptic plasticity, stroke recovery, neuronal maintenance, oxidative/inflammatory protection and cognitive preservation.14
Mood. Mood elevation, anxiety reduction, stress management and emotional resilience.14
Community reports Unvalidated
Pep-Pedia discusses focus and fatigue interest.2
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
A 2025 regulatory classification proposal names Adamax. No exact-compound clinical study was verified.
- Checked
- 2026-10-12
- Search
- "Adamax" peptide study clinical 2025 2026
- Catalog
- Pep-Pedia ↗ · 11 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “580 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1Medicines Classification Committee: peptide classification proposalPrimary source checked
AI-PREPARED SUMMARY
The proposal names Adamax and Semax among ACTH analogues marketed for cognitive enhancement; it is a classification document, not evidence of efficacy or authorization.
Regulatory mention is not clinical validation
A New Zealand classification proposal identifies Adamax among marketed ACTH analogues. No exact-compound controlled human study was verified in this targeted search.
Additional research · Checked 2026-10-12
2Pep-Pedia: AdamaxCommunity source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
3Adamax Stroke Recovery Preliminary ReportsPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Better post-stroke neurological outcomes are claimed, but participant counts, doses and an identifiable controlled trial are not supplied in the card.
Reported population / model
Humans
Reported study details
Dosage not specified · Variable administration · Observational · Additional card metadata — BDNF and TrkB Receptor Upregulation Studies: In vitro and animal models·Various concentrations·BDNF expression measured
BDNF and TrkB Receptor Upregulation Studies: Higher hippocampal BDNF and TrkB responsiveness are claimed from laboratory work; clinical cognitive benefit is not established.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4BDNF and TrkB Receptor Upregulation StudiesPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Higher hippocampal BDNF and TrkB responsiveness are claimed from laboratory work; clinical cognitive benefit is not established.
Reported population / model
In vitro and animal models
Reported study details
Various concentrations · BDNF expression measured · Additional card metadata — Adamax Stroke Recovery Preliminary Reports: Humans·Dosage not specified·Variable administration·Observational
Adamax Stroke Recovery Preliminary Reports: Better post-stroke neurological outcomes are claimed, but participant counts, doses and an identifiable controlled trial are not supplied in the card.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Neurotransmitter Modulation in Cognitive EnhancementPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Changes in dopamine, norepinephrine and serotonin are described in animal models; their clinical relevance is unresolved.
Reported population / model
Animal models
Reported study details
Various doses · Neurotransmitter levels measured
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Microtubule Assembly and Stability Research (ADNP Connection)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Microtubule binding and assembly are proposed from ADNP-related work; applicability to the marketed Adamax compound needs verification.
Reported population / model
Cellular studies
Reported study details
ADNP-derived mechanisms · Microtubule protein binding
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Semax in Stroke Recovery - BDNF Elevation (Parent Compound)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Semax recipients reportedly had higher plasma BDNF and better motor and independence measures. This is parent-compound evidence, not an Adamax trial.
Reported population / model
Humans
Reported study details
110 patients · 6000 mcg/day intranasal · Two 10-day courses · Additional card metadata — Semax Cognitive Enhancement in Fatigued Volunteers (Parent Compound): Humans·16 mcg/kg intranasal·Single dose·24-hour effects
Semax Cognitive Enhancement in Fatigued Volunteers (Parent Compound): The source reports memory-test accuracy of 71% with Semax versus 41% in controls and effects lasting 24 hours; Adamax was not tested.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Semax Cognitive Enhancement in Fatigued Volunteers (Parent Compound)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports memory-test accuracy of 71% with Semax versus 41% in controls and effects lasting 24 hours; Adamax was not tested.
Reported population / model
Humans
Reported study details
16 mcg/kg intranasal · Single dose · 24-hour effects · Additional card metadata — Semax in Stroke Recovery - BDNF Elevation (Parent Compound): Humans·110 patients·6000 mcg/day intranasal·Two 10-day courses
Semax in Stroke Recovery - BDNF Elevation (Parent Compound): Semax recipients reportedly had higher plasma BDNF and better motor and independence measures. This is parent-compound evidence, not an Adamax trial.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Adamax: A Novel Semax Derivative with Enhanced Nootropic PropertiesPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Better post-stroke neurological outcomes are claimed, but participant counts, doses and an identifiable controlled trial are not supplied in the card.
Reported population / model
Humans
Reported study details
Dosage not specified · Variable administration · Observational · Additional card metadata — BDNF and TrkB Receptor Upregulation Studies: In vitro and animal models·Various concentrations·BDNF expression measured
BDNF and TrkB Receptor Upregulation Studies: Higher hippocampal BDNF and TrkB responsiveness are claimed from laboratory work; clinical cognitive benefit is not established.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Adamax & P21: Two New Nootropic Peptides To Watch CloselyPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Microtubule binding and assembly are proposed from ADNP-related work; applicability to the marketed Adamax compound needs verification.
Reported population / model
Cellular studies
Reported study details
ADNP-derived mechanisms · Microtubule protein binding
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11The Regulatory Peptide Semax: Nootropic and Neuroprotective Effects (Parent Compound)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Semax recipients reportedly had higher plasma BDNF and better motor and independence measures. This is parent-compound evidence, not an Adamax trial.
Reported population / model
Humans
Reported study details
110 patients · 6000 mcg/day intranasal · Two 10-day courses · Additional card metadata — Semax Cognitive Enhancement in Fatigued Volunteers (Parent Compound): Humans·16 mcg/kg intranasal·Single dose·24-hour effects
Semax Cognitive Enhancement in Fatigued Volunteers (Parent Compound): The source reports memory-test accuracy of 71% with Semax versus 41% in controls and effects lasting 24 hours; Adamax was not tested.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Peptide Semax Affects the Expression of Genes Related to Immune and Vascular Systems in Rat Brain Ischemia (Parent Compound)Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
13Rapid Elevation of BDNF Expression Following Semax Administration (Parent Compound)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Semax recipients reportedly had higher plasma BDNF and better motor and independence measures. This is parent-compound evidence, not an Adamax trial.
Reported population / model
Humans
Reported study details
110 patients · 6000 mcg/day intranasal · Two 10-day courses · Additional card metadata — Semax Cognitive Enhancement in Fatigued Volunteers (Parent Compound): Humans·16 mcg/kg intranasal·Single dose·24-hour effects
Semax Cognitive Enhancement in Fatigued Volunteers (Parent Compound): The source reports memory-test accuracy of 71% with Semax versus 41% in controls and effects lasting 24 hours; Adamax was not tested.
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here. Multiple reference cards share this URL; their attribution may differ.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
14Pep-Pedia: Adamax — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12